CDK4 and breast carcinoma: We performed a prospective subgroup analysis of the Vax-On-Third-Profile study to investigate longitudinal changes in antibody titers following full-course of mRNA-BNT162b2 (tozinameran) immunization in patients with advanced breast cancer receiving CDK4/6 inhibitors or HER2-targeted agents.